Carbetocin
Carbetocin is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target oxytocin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postpartum hemorrhage | D006473 | O72 | 2 | 1 | 2 | 10 | 17 | 32 | |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | 2 | 2 | 5 |
Uterine inertia | D014593 | EFO_1001863 | O62.2 | — | — | — | 2 | 1 | 3 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | 2 | — | 2 |
Uterine myomectomy | D063186 | — | — | — | 1 | — | 1 | ||
Pregnancy complications | D011248 | — | — | — | 1 | — | 1 | ||
Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | — | 1 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | 1 | — | 1 |
Surgical blood loss | D016063 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 2 | — | 1 | 3 |
Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | 1 | 1 | — | — | 2 |
Cesarean section | D002585 | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
High-risk pregnancy | D018566 | 1 | — | — | — | 1 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CARBETOCIN |
INN | carbetocin |
Description | Carbetocin is oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. It has a role as an oxytocic. |
Classification | Protein |
Drug class | oxytocin derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O |
Identifiers
PDB | — |
CAS-ID | 37025-55-1 |
RxCUI | — |
ChEMBL ID | CHEMBL3301668 |
ChEBI ID | 59204 |
PubChem CID | 16681432 |
DrugBank | DB01282 |
UNII ID | 88TWF8015Y (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 584 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more